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Abstract
Objective Persistent pain and loss of shoulder function are common adverse effects to breast cancer treatment, but the extent of
these issues in comparison with healthy controls is unclear for survivors beyond 1.5 years after treatment. The purpose of this
study was to benchmark differences in pressure pain thresholds (PPT), maximal isokinetic muscle strength (MIMS), and active
range of motion (ROM) of females with persistent pain ≥1.5 years after breast cancer treatment (BCS) compared with pain-free
matched controls (CON), and examine the presence of movement-evoked pain (MEP) during assessment of MIMS.
Methods The PPTs of 18 locations were assessed using a pressure algometer and a numeric rating scale was used to assess
intensity of MEP. Active ROM and MIMS were measured using a universal goniometer and an isokinetic dynamometer,
respectively.
Results A two-way analysis of variance revealed that PPTs across all locations, MIMS for horizontal shoulder extension/flexion
and shoulder adduction, active ROM for shoulder flexion, horizontal shoulder extension, shoulder abduction, and external
shoulder rotation were significantly lower for BCS compared with CON (P < 0.05). MEP was significantly higher for BCS
and MEP intensity had a significant, negative correlation with PPTs (P < 0.01).
Discussion/conclusion BCS with persistent pain ≥1.5 years after treatment demonstrates widespread reductions in PPTs and
movement-specific reductions in MIMS and active ROM of the affected shoulder, along with MEP during physical performance
assessment.
Implications for cancer survivors BCSwith persistent pain ≥1.5 years after treatment shows signs of central sensitization and may
benefit from individualized rehabilitation.
Keywords Breast cancer survivors .Movement-evoked pain .Muscle strength . Range ofmotion
Introduction
Persistent pain after treatment for breast cancer is a common
problem affecting 25–60% of the patients for years after the
initial treatment [1]. Persistent pain refers to pain in and
around the area of surgery (e.g., chest, shoulder, arm, and side
of body) lasting more than 3 months [2] that often cause con-
siderable physical disability [3]. Pain after treatment for breast
cancer is a frequent source of decreased physical function [4],
and is a primary cause of upper limb impairments [4], which
lead to limitations in activities of daily living [5] as well as
reduced quality of life. Furthermore, pain has been associated
with mechanical hyperalgesia [6] and loss of strength and
range of motion (ROM) in the affected shoulder [7], which
may further exacerbate upper limb impairments [8]. Upper
body strength and ROM contribute to the functional status
by promoting adequate scapula-humeral mobility and stability
[9], and hence, it could be speculated that pain alters function-
al shoulder recovery in patients. Indeed, pain intensity and
sensitivity have been associated with upper limb dysfunction
one and a half years after treatment for breast cancer [10],
suggesting that persistent pain has long lasting negative ef-
fects on shoulder function in breast cancer survivors (BCS).
However, De Groef et al. [10] are the only study to elaborate
on the long-term contribution of pain to shoulder dysfunction
in BCS, that we are aware of, and little is known about the
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influence of pain on shoulder function beyond 1.5 years after
the initial treatment.
Importantly, kinesiophobia was recently reported as the
main contributor to-pain related disability in mid- to long-
term BCS [11], implying that BCS experience persistent pain
during the performance of physical tasks, i.e., movement-
evoked pain (MEP). Movement-evoked pain refers to pain
that is experienced in response to a physical challenge [12]
and can influence force production through activation of the
nociceptors and of the pain processing network in the brain
[13]. Consequently, MEP can inhibit muscular strength and
impair movement. Furthermore, higher MEP have previously
been associated with lower levels of physical performance and
increased mechanical pain sensitivity in patients with painful
knee osteoarthritis [14]. Therefore, assessment and consider-
ation of MEP could potentially increase the clinical value of
shoulder function tests and pain assessments in BCS.
However, although abundant evidence exists for the impact
of pain on physical functional performance [14], no studies to
date have examined MEP during functional physical perfor-
mance assessments, such as shoulder strength, among BCS
with persistent pain after treatment. Moreover, to the best of
our knowledge, no studies have assessed pain perception and
shoulder function simultaneously in BCS with persistent pain
beyond 1,5 years after treatment, despite evidence of shoulder
dysfunction and pain after treatment for breast cancer
persisting for up to 6 [15] and 8 [1] years respectively.
Therefore, the purpose of this study was 3-fold; (1) to as-
sess pressure pain sensitivity, shoulder strength, and ROM in
BCS with self-reported pain ≥1.5 years after treatment com-
pared with asymptomatic female controls; (2) investigate the
presence of MEP during the assessments of shoulder strength;
and (3) determine if this is related to mechanical pain sensi-
tivity. We hypothesized that BCS compared with matched
controls would be characterized by deficits in shoulder func-
tion, i.e., mechanical hyperalgesia, lower levels of shoulder
strength, and active ROM, and exhibit MEP related to me-
chanical hyperalgesia. Such information is a pre-requisite for
proper design and development of specific exercise interven-
tions and rehabilitation programs for efficient rehabilitation




Forty-two women participated in this case-control study,
equally distributed in two groups: BCS (N = 21, mean (CI:
95%); age (years) = 57.4 (54;60.8), height (cm) = 167.9
(165.5;170.2), body mass index (kg/m2) = 27.6 (25.3;29.8)),
and CON (N = 21, mean (CI: 95%); age (years) = 60
(55.5;64.5), height (cm) = 165.5 (162.8;168.2), body mass
index (kg/m2) = 27.1 (24.9;29.2)). The same BCS group par-
ticipated in a separate reliability study assessing absolute and
relative reliability of pressure pain threshold (PPT), maximal
isokinetic muscle strength (MIMS), and active ROM [16].
Participants for BCS were recruited by means of a database
letter through the national database managed by the Danish
Breast Cancer corporate Group. Women were eligible for in-
clusion in the BCS group if theywere as follows: (i) diagnosed
with primary unilateral breast cancer (grades I–IIIA); (ii) adult
women at least 18 years of age; (iii) treated for breast cancer
(i.e., surgery and possible adjuvant chemo and/or radiothera-
py) at least 18 months before the start of the study; (iv)
experiencing pain (self-reported) in the areas of the breast,
shoulder, axilla, arm, and/or side of body with an intensity
of ≥3 on a numeric rating scale (0 = no pain, 10 = worst pain
imaginable); (v) women without signs of cancer recurrence;
and (vi) reading, writing, and speaking Danish. Reasons for
ineligibility were as follows: (i) breast surgery for cosmetic
reasons or prophylactic mastectomy; (ii) bilateral breast can-
cer; (iii) recurrence of cancer; (iv) lymphedema; (v) other ad-
verse medical conditions with potential influence on the study,
or (vi) previous diagnosis of fibromyalgia syndrome. Controls
were asymptomatic (pain-free) female volunteers with no pre-
vious history of cancer matched to the BCS group as well
possible for age (mean difference, range: 2.6, 0–7 years) and
bodymass index (mean difference, range: 0.5, 0.0–2.2 kg/m2).
Women were eligible for inclusion in the control group if they
were as follows: (i) adult women at least 18 years of age and
(ii) reading, writing, and speaking Danish. Reasons for ineli-
gibility were as follows: (i) pregnancy; (ii) drug addiction,
e.g., continued use of cannabis, opioids, or other substances
taken for a non-medical purpose; (iii) presence of signs or
symptoms of musculoskeletal pain; (iv) history of persistent
pain or trauma in the upper body; (v) adverse medical condi-
tions with potential influence on the study (e.g., chronic fa-
tigue syndrome); (or vi) participation in other pain trials
throughout the study period. All the participants were
instructed to avoid physical activity and consumption of alco-
hol, caffeine, nicotine, or analgesics (e.g., paracetamol, ibu-
profen, or codeine) in the last 24 h prior to the experiments.
The study was conducted in accordance with STROBE guide-
lines [17]. The study protocol was approved by the local
Ethics Committee (N-20180090) and conducted according
to the Declaration of Helsinki. Following a detailed written
and verbal explanation of the experimental risks, the partici-
pants gave their written informed consent prior to participat-
ing in the study.
Study design
Each participant completed a familiarization session (FS), and
an experimental session (ES) separated by 1 week (Fig. 1).
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Baseline characteristics (anthropometrics, demographics,
physical, health, surgical, medical, and pain profile) and phys-
ical activity level (IPAQ) [18] were collected during FS only,
while PPT, active ROM, and MIMS were measured during
both FS and ES (Fig. 1). PPT, active ROM, and MIMS were
collected during FS for familiarization purposes only and not
included in the further analysis. To avoid a confounding in-
fluence of excessive fatigue during the experimental sessions,
measurements were performed unilaterally on the operated
side for BCS and the left/right distribution were matched for
CON. The resulting no. of assessments performed on the dom-
inant side were 9 (34%) and 8 (38%) for BCS and CON,
respectively. The participants were blinded to the measures
of PPT, active ROM, and MIMS, and all assessments were
performed by the same researcher who had received weekly
training in the three months leading up to the study (GHFR,
not blinded).
Outcomes
Movement evoked pain (MEP) intensity was rated after each
series of MIMS on a 0–10 Numeric Pain Rating Scale
(NPRS), where 0 corresponded to “no pain” and 10 to “worst
pain imaginable” [19]. The cut-off scores used as reference
were as follows: 0 = no pain; 1–3 = mild; 4–6 = moderate; 7–
10 = severe pain [20].
Pressure pain thresholds are a reliable measure of mechan-
ical pain sensitivity in BCS with intra class correlation coef-
ficients (ICC) ranging from 0.88 to 0.97 [16], and were ob-
tained in agreement with Rasmussen et al. [16]. Hence, PPTs
were measured unilaterally across 17 points, located on the
dorsal (6 points) and ventral (11 points) parts of the chest,
shoulder, and neck region (Fig. 1). In addition, a distant ref-
erence point was located on the ipsilateral tibialis anterior
muscle to assess the potential presence of generalized
hyperalgesia [21]. All PPT measurements were collected
using a pressure algometer (Somedic AB, Farsta, Sweden)
with a 1 cm2 probe and a constant incremental pressure rate
of 30 kPa/s. The participants were instructed to press a hand-
held button immediately when the sensation changed from
pressure to pain. The measurements were performed twice in
predefined order (P1-18), and a third time if the coefficient of
variance was ≥20%. There were approx. 6 min between mea-
surements made over the same point to avoid temporal sum-
mation of pain. Pressure pain threshold map of the dorsal and
ventral regions was constructed from the mean PPT values of
the points located on the dorsal and ventral muscles respec-
tively by measuring the distance d between C7 and acromion,
and the distance e between acromion and the sternoclavicular
joint for each participant and computing the inter-distance
between points. Inverse distance–weighted interpolation was
then applied to obtain a map of the spatial pressure pain dis-
tribution of each region [22].
Body mass index (kg/m2) was calculated from height and
body mass measured at the familiarization session. The fat-
free mass (FFM), body fat mass (BFM), skeletal muscle mass
(SMM), and body fat percentage (BF%) of each participant
were computed using direct segmental multifrequency (DSM)
bioelectrical impedance analysis (BIA) (InBody 370,
Biospace, Seoul, Korea), in agreement with the manufac-
turer’s recommendations. DSM-BIA is considered valid and
reliable for body composition measures in the general
Fig. 1 Pressure pain threshold grids. Schematic representation of the
dorsal (a) and ventral (b) grids for pressure pain threshold (PPT) assess-
ments. The PPTs of the dorsal region were measured over 6 points located
on the trapeziusmuscle (P1-P2), infraspinatus (P3), posterior deltoid (P4),
latissimus dorsi (P5), and lateral deltoid (P6). The PPTs of the ventral
region were measured over 11 points located on the anterior deltoid (P7-
P10) and pectoralis major (P11-P17). d = distance between the seventh
cervical vertebra (C7) and acromion (ACR), e = distance between the
sternoclavicular joint (SCJ) and acromion (ACR), and C = the summed
distance between P11 and P12, P12 and P14, and P14, and P16 on the x-
axis
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population when compared to dual-energy x-ray absorptiom-
etry (DXA) [23].
Active ROM was measured with a universal goniometer
for six movement directions: (1) supine shoulder flexion, (2)
supine horizontal shoulder flexion, (3) horizontal shoulder
extension, (4) seated upright shoulder abduction, (5) supine
internal shoulder rotation, and (6) supine external shoulder
rotation in agreement with the protocol of Rasmussen et al.
[16]. Supine measurements were performed with the knees
flexed to flatten the lumbar spine, and with manual stabiliza-
tion of the scapulae during assessment of inter/external shoul-
der rotation. For the seated upright measurements, participants
were positioned seated firmly against the back of the chair to
ensure trunk stabilization, and instructed to maintain a neutral
head position. For further details on anatomical starting posi-
tions of the shoulder and arm, see Rasmussen et al. [16].
Goniometric measurements of active ROM are reliable in
BCS (ICCs: 0.66–0.97) [16], and were performed by the same
researcher by aligning the goniometer arms between bony
landmarks (e.g., olecranon process and ulnar styloid of the
forearm, and medial epicondyle of the humerus) and position-
ing the fulcrum of the goniometer above the approximate pro-
jection of the given joint center on the movement plane.
Similar to PPT, the assessments were performed twice over
two rounds in systematic order and a third time if the mea-
surements had a coefficient of variance ≥20%. The mean
ROM values were calculated for each movement direction.
Maximal isokinetic muscle strength (MIMS) can also be
measured reliably in BCS (ICCs: 0.62–0.92) [16], and was
collected for eight movement directions: (1) supine shoulder
flexion, (2) supine shoulder extension, (3) supine horizontal
shoulder extension, (4) supine horizontal shoulder flexion, (5)
seated shoulder abduction, (6) seated shoulder adduction, (7)
supine internal shoulder rotation, and (8) supine external
shoulder rotation. All measurements were performed using
an isokinetic dynamometer (Humac Norm, model 770,
Computer Sports Medicine Inc., Stoughton, USA). Each par-
ticipant was familiarized with the protocol during FS, and
performed a brief (approx. 10 min) general warm up of vari-
ous stretching exercises for the prime movers prior to testing.
This was followed by a series of 10 consecutive contractions
with submaximal progressive effort followed by a series of
five consecutive contractions at maximal effort for each mus-
cle group with a 2-min rest period between series. Rest be-
tween measurements for each movement direction consisted
of the time required for readjustment of the dynamometer
(approximately 5 min). All isokinetic strength testing was
conducted at a speed of 600/s through the ROM previously
measured for each movement direction. The first repetition of
each maximal trial was discarded, and mean peak torque was
computed for the remaining four at a fixed joint angle. Mean
peak torque was then normalized to FFM and expressed as
Nm/kg FFM. Gravity correction was performed for each
participant prior to the series of assessments. For a more de-
tailed description about strength measurements, see
Rasmussen et al. [16].
Statistical analysis
The minimum required sample size to detect a significant
difference in PPT between groups, assuming an alpha level
of 0.05, a beta level of 0.80 and a large effect size of 0.52
estimated from the pectoral PPTs reported by Caro-Moran
et al. [6], was determined to be at least 32 (16 per group).
To account for a potential drop out of 20–30%, 42 participants
were enrolled in the study. Independent samples t tests were
used to compare age and BMI between groups. A two-way
analysis of variance (ANOVA) was performed to investigate
potential differences between groups. PPT was used as depen-
dent factor with anatomical location (P1-18, mean dorsal, &
mean ventral) and group (BCS, CON) as independent factors.
Similarly, active ROM and MIMS were used as dependent
factors with movement direction (1–6 & 1–8) and group
(BCS, CON) as independent factors. In the case of a signifi-
cant interaction effect, simple main effects were analyzed
within each combination of the other effects through univari-
ate tests based on linearly independent pairwise comparisons
among the estimated marginal using the overall error term of
the two-way ANOVA. If no significant interaction effect was
found, main effects were reported. Post hoc analyses were
performed as univariate analyses with Bonferroni correction
for multiple comparisons = α/n. The Shapiro-Wilks test of
normality was applied to test the assumption of normal distri-
bution and homogeneity of variance was tested through
Levene’s Test of Equality of Error Variances. If the assump-
tions of normality and equal variance were violated, a Mann-
Whitney U rank based nonparametric test with Holm-
Bonferroni sequential correction for multiple comparisons
was applied to assess between group differences for each out-
comemeasure = α / (n – rank +1). Associations between PPTs
and MEP assessments were explored through a Pearson's
product-moment correlation analysis or Spearman’s rank or-
der correlation. Assumptions of linearity and outliers were
determined from visual inspection and the Shapiro-Wilks test
of normality was applied to test the assumption of normal
distribution. Since the afore-mentioned assumptions were vi-
olated, only Spearman’s rank order correlation was applied.
All statistical procedures were conducted in IBM SPPS
Statistics (26.0 version; IBM Corp., Armonk, NY, USA). A
P value less than 0.05 was considered statistically significant.
Differences are expressed as mean (confidence interval (CI)
95%) and median (25–75th percentile) for parametric and non-
parametric tests, respectively. Effect size estimates are report-
ed as partial eta squared (partial η2), and interpreted according
to Cohen [24] in which ≥0.01 to < 0.06, ≥ 0.06 to < 0.14 and ≥
0.14 correspond to small, medium, and large effect sizes,
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respectively. Similarly, correlation coefficients were
interpreted in accordance with the guidelines of Cohen, where
>0.1 to < 0.3, 0.3 to <0.5 and > 0.5 denote a small, moderate,
or large correlational effects, respectively. Missing data points
were omitted from the above analyses.
Results
The independent sample t tests revealed no statistically signif-
icant difference between groups for age (t (− 0.974), P =
0.336, partial η2 = 0.01) and BMI (t (0.338), P = 0.737, partial
η2 = 0.00). The sociodemographic, physical, and health char-
acteristics of BCS and CON are reported in the supplementary
information (Appendix). For detailed information on surgical,
medical, and pain profile of BCS, see supporting material for
Rasmussen et al. [16].
Mean PPTs for BCS and CON are reported in Table 1. The
two-way ANOVA revealed no significant interaction effect
between group and location, (F (19,800) = 0.683, P = 0.838,
partial η2 = 0.016). A significant main effect was found for
group (F (1800) = 375,951, P = ≤ 0.001, partial η2 = 0.320)
and location (F (19,800) = 6062, P ≤ 0.001, partial η2 =
0.126). The PPTs were on average 49% lower for BCS than
for CON across all locations (mean (95%CI) = − 136.3 kPa (−
150.1: − 122.5)). This group difference was further visualized
by the PPT maps (Fig. 2), which also revealed similar spatial
distribution of mechanical pain sensitivity between groups.
The most sensitive area was located on the inferior portion
of the pectoralis major on the ventral region for both groups,
whereas the least sensitive areas were located at the posterior
deltoid and the latissimus dorsi on the dorsal region for BCS
and CON respectively (Fig. 2).
Mean active ROM for BCS and CON are reported in
Table 2. The two-way ANOVA revealed a significant interac-
tion effect between group and movement, (F (5240) = 3515, P
= 0,004, partial η2 = 0.068), demonstrating that group differ-
ences in active ROM were movement dependent and reduced
for BCS in some, but not all movement directions (see
Table 3). Simple main effects analyses showed that mean
active ROM of BCS was significantly lower when compared
to CON for flexion (F (5240) = 10,066, P = 0.002, partial η2 =
0.040), horizontal extension (F (5240) = 16,793, P ≤ 0.001,
partial η2 = 0.065), abduction (F (5240) = 5935, P = 0.016,






BCS (N = 21)
Mean (95% CI)






Point 1 164.2 (130.0; 198.3) 300.0 (241.3; 358.7) − 135.8 (− 201.6; − 70.1)* 0.023
Point 2 178.1 (135.6; 220.6) 319.2 (257.8; 380.5) − 141.1 (− 213.4; − 68.8)* 0.025
Point 3 168.6 (135.4; 201.8) 329.9 (259.5; 400.2) − 161.2 (− 236.6; − 85.8)* 0.032
Point 4 194.7 (144.7; 244.6) 346.2 (268.0; 424.3) − 151.5 (− 241.4; − 61.6)* 0.028
Point 5 151.3 (117.6; 185.1) 372.2 (295.7; 448.6) − 220.8 (− 301.7; − 139.9)* 0.058
Point 6 159.3 (119.9; 198.7) 294.2 (241.5; 346.8) − 134.9 (− 198.6; − 71.1)* 0.022
Mean.Dors 169.4 (130.4; 208.4) 326.9 (260.2; 393.6) − 157.6 (− 219.3; − 95.8)* 0.030
Point 7 139.4 (115.4; 163.5) 284.2 (222.6; 345.9) − 144.8 (− 208.9; − 80.7)* 0.026
Point 8 126.7 (103.9; 149.4) 234.4 (190.7; 278.0) − 107.7 (− 155.4; − 60.0)* 0.014
Point 9 131.1 (106.5; 155.7) 257.3 (205.4; 309.2) − 126.2 (− 181.8; − 70.5)* 0.020
Point 10 131.9 (104.1; 159.7) 245.7 (204.7; 286.8) − 113.9 (− 161.9; − 65.8)* 0.016
Point 11 125.6 (92.1; 159.0) 235.9 (188.5; 283.4) − 110.4 (− 166.6; − 54.1)* 0.015
Point 12 114.5 (78.2; 150.9) 227.9 (185.0; 270.8) − 113.4 (− 167.9; − 58.9)* 0.016
Point 13 109.0 (70.6; 147.3) 223.9 (181.1; 266.8) − 115.0 (− 170.7; − 59.3)* 0.016
Point 14 110.6 (88.6; 132.7) 227.9 (180.3; 275.5) − 117.3 (− 168.1; − 66.5)* 0.017
Point 15 93.6 (73.8; 113.3) 244.4 (192.9; 295.9) − 150.8 (− 204.2; − 97.3)* 0.028
Point 16 112.2 (85.0; 139.4) 232.5 (184.4; 280.7) − 120.3 (− 173.9; − 66.7)* 0.018
Point 17 99.4 (74.5; 124.3) 230.9 (176.0; 285.7) − 131.5 (− 189.9; − 73.1)* 0.021
Mean.Vent 117.6 (89.5; 145.7) 240.5 (192.1; 288.9) − 122.8 (− 184.6; − 61.1)* 0.027
Reference
point
193.9 (154.1; 233.7) 343.2 (267.9; 418.5) − 149.3 (− 211.0; − 87,6)* 0.019
PPT pressure pain threshold,Mean.Dorsmean dorsal shoulder,Mean.Ventmean ventral shoulder, CI confidence
interval, BCS breast cancer survivors, CON controls
*P < 0.001 (post hoc analyzes: differences in PPT between groups)
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partial η2 = 0.024), and external rotation (F (5240) = 20,261, P
≤ 0.001, partial η2 = 0.078). Active ROMwas on average 10%
lower for BCS than for con across these movement directions.
MeanMIMS for BCS and CON is reported in Table 3. The
two-way ANOVA revealed a significant interaction effect be-
tween group and movement, (F (7312) = 4116, P ≤ 0.001,
partial η2 = 0.085) demonstrating that group differences in
MIMS were movement dependent and reduced for BCS in
some, but not all movement directions (see Table 3). Simple
main effect analyses showed that mean MIMS of BCS was
significantly lower when compared to CON for horizontal
shoulder extension (F (1312) = 14,314, P ≤ 0.001, partial η2
= 0.044), horizontal shoulder flexion (F (1312) = 10,303, P =
0.001, partial η2 = 0.032), and shoulder adduction (F (1312) =
23,232, P ≤ 0.001, partial η2 = 0.069). MIMS was on average
11% lower for BCS than for con across these movement
directions.
The Mann-Whitney U test revealed that intensity of MEP
was significantly higher for BCS when compared to CON
during shoulder extension/flexion (adj. P = 0.004, partial η2
= 0.269), horizontal shoulder extension/flexion (adj. P =
0.004, partial η2 = 0.276), shoulder abduction/adduction
(adj. P = 0.004, partial η2 = 0.272), and for internal/external
shoulder rotation (adj. P = 0.004, partial η2 = 0.301). Group
difference in median [25th; 75th percentiles] was 4.0 [0.0; 5.8]
during shoulder extension/flexion, 4.0 [0.0; 7.0] during hori-
zontal shoulder extension/flexion, 4.5 [0.0; 5.0] during abduc-
tion/adduction, and 4.5 [0.3; 5.8] during internal/external ro-
tation. The Spearman’s rank order correlation revealed a sig-
nificant, large negative correlation effect between the intensity
Fig. 2 Pressure pain threshold maps. Mean pressure pain threshold (PPT)
maps from the eleven anatomical locations on the ventral shoulder region,
and six locations on the dorsal shoulder region of the BCS (a and b) and
control (c and d) groups. Note the significantly lower PPT for BCS
compared with CON (p < 0.01)





BCS (N = 21)
Mean (95% CI)






Flexion 158.5 (151.3; 165.7) 171.2 (167.8; 174.6) − 12.7 (− 20.4; − 5.0)** 0.040
Hor. flexion 21.5 (19.5; 23.4) 21.1 (19.3; 23.0) 0.3 (− 2.3; 2.9) 0.000
Hor. extension 97.5 (90.1; 104.8) 113.9 (110.7; 117.1) − 16.5 (− 24.2; − 8.7)* 0.065
Abduction 144.2 (134.8; 153.6) 154 (145.4; 162.6) − 9.8 (− 22.1; 2.5)*** 0.024
Internal rotation 43.2 (37.2; 49.3) 45.3 (42.5; 48.1) − 2.1 (− 8.5; 4.4) 0.001
External rotation 72.4 (65.8; 79.1) 90.5 (84.5; 96.5) − 18.1 (− 27.8; − 9.4)* 0.078
ROM range of motion, CI confidence interval, BCS breast cancer survivors, CON controls
0 Joint angle
*P < 0.001; **P < 0.01; ***P < 0.05 (post hoc analyses: differences in ROM between groups)
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of movement evoked pain and the grand mean PPT in BCS for
horizontal flexion/extension MEP (ρ [18], − 0.572, P =
0.008), and abduction/adduction MEP (ρ [18], − 0.536, P =
0.015), but not for flexion/extension MEP (ρ [18], − 0.244, P
= 0.299) and internal/external rotation MEP (ρ [18], − 0.284,
P = 0.225).
Discussion
This study examined differences between BCS with per-
sistent pain ≥1.5 years after treatment and asymptomatic
controls for mechanical pain sensitivity, shoulder strength,
active ROM, and MEP. As hypothesized, BCS with self-
reported pain ≥1.5 years after treatment demonstrated sig-
nificant reductions in pressure pain thresholds (− 49%),
maximal isokinetic muscle strength (− 11%), and active
ROM (− 10%) in the affected shoulder. The effect size
(partial η2) for interaction- and main effects was 0.320
(large) for PPT, 0.068 (moderate) for active ROM, and
0.085 (moderate) for MIMS. Furthermore, the shoulder
strength assessments elicited a moderate movement
evoked pain response in BCS (i.e., NPRS = 4–6), which
had a large negative correlation effect with pressure pain
thresholds. These results provide further evidence that
pain and loss of function in the affected shoulder are
long-lasting adverse effects to breast cancer treatment
and indicate that BCS ≥1.5 years post-treatment may ben-
efit from specific exercise training for the shoulder girdle.
Furthermore, the results of this study provide preliminary
evidence that assessment of physical performance can
elicit an MEP response in BCS with persistent pain after
treatment. This response appears to be associated with the
extent of mechanical pain sensitivity and may represent a
relevant clinical outcome to monitor when investigating
physical function and prescribing physical activity and
exercise for this population.
Pain
The PPTs observed in the present study are similar to those
previously reported for BCS [6] and healthy individuals [25].
In agreement with Caro-Moran et al. [6], we found that the
PPTs of BCS were considerably lower across all anatomical
locations including a remote point over the tibialis anterior
muscle when compared with CON, which demonstrate a
widespread mechanical hyperalgesia. These differences in
PPT were greater than the minimum detectable change
(MDC) previously reported to range from 33.2 to 78.2 kPa
[16], demonstrating a clinically significant increase in me-
chanical pain sensitivity in BCS. This has previously been
suggested as indicative of a central sensitization mechanism
in BCS with pain after treatment [6], a notion which is further
supported by the marked reduction in PPTmeasured distant to
the surgical area (i.e., tibialis anterior). Hence, the similar
spatial mechanical pain sensitivity between groups, as illus-
trated by the PPT maps (Fig 2), could be speculated to reflect
an otherwise normal difference in spatial PPT distribution
between shoulder regions for BCS, which is amplified by
alterations in pain- modulatory processes [26]. In contrast,
potential nerve damage from the surgical and/or adjuvant ther-
apy has previously been suggested as possible explanations
[21], implying a more localized source of the greater sensitiv-
ity observed for the ventral shoulder region in BCS.
Sign of central sensitization could also explain the MEP
response reported for BCS for all movement directions when
measuring muscle strength, as centrally-mediated pain path-
ways are implicated in MEP [27]. Consequently, discomfort
associated with strenuous physical activity could intensify to
perceived pain, or an exacerbation of perceived pain. This
notion is supported by the strong, significant correlations ob-
served between PPT and MEP for horizontal extension/
flexion and abduction/adduction, indicating that greater me-
chanical pain sensitivity is associated with higher intensity of
MEP in BCS. Thus, the mechanical pain sensitivity (PPT) and
Table 3 Mean maximal
isokinetic muscle strength across
movement directions
Fixed position normalized
peak torque (Nm/kg FFM)
BCS (N = 20)
Mean (95% CI)






Extension (630) 0.47 (0.44; 0.50) 0.49 (0.45; 0.54) − 0.03 (− 0.08; 0.03) 0.002
Flexion (630) 0.53 (0.48; 0.58) 0.54 (0.49; 0.58) − 0.01 (− 0.07; 0.05) 0.000
Hor. extension (330) 0.43 (0.37; 0.49) 0.54 (0.50; 0.59) − 0.12 (− 0.19; − 0.05) * 0.044
Hor. flexion (80) 0.56 (0.48; 0.63) 0.66 (0.61; 0.70) − 0.10 (− 0.18; − 0.01)** 0.032
Abduction (580) 0.55 (0.49; 0.61) 0.51 (0.47; 0.56) 0.04 (− 0.03; 0.11) 0.004
Adduction (580) 0.40 (0.36; 0.45) 0.55 (0.51; 0.59) − 0.15 (− 0.21; − 0.09) * 0.069
Internal rotation (110) 0.25 (0.22; 0.29) 0.29 (0.27; 0.30) − 0.03 (− 0.07; 0.00) 0.003
External rotation (230) 0.25 (0.21; 0.28) 0.26 (0.24; 0.29) − 0.02 (− 0.06; 0.03) 0.001
0 Joint angle from anatomical zero, Nm Newton meter, FFM fat-free mass, CI confidence interval, BCS breast
cancer survivors, CON controls
*P < 0.001; **P < 0.01(post hoc analyzes differences in MIMS between groups)
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MEP observed in the present study could be interpreted as
further evidence for the presence of central sensitization in
women with persistent pain after breast cancer treatment.
Therefore, MEP during physical performance assessments of
patients with signs of central sensitization, such as BCS with
persistent pain, may be a relevant clinical outcome to measure
in order to improve our understanding of the influence of
central sensitization pain on physical function and task
performance.
In addition, monitoring MEP could be useful to determine
the appropriate dose of exercise in this population and possi-
bly reduce or avoid fear of movement that may otherwise
result in pain related disability in mid- to long-term BCS
[11]. As highlighted by Campbell et al. [28], there is currently
little evidence to guide the appropriate modality (strength,
aerobic, flexibility, etc.) or dose (volume, intensity, frequency,
etc.) of exercise for cancer survivors, and both too little and
too much exercise could be suboptimal for tissue health and/or
pain management [27]. This point may be particularly impor-
tant when prescribing exercise or physical/leisure activities for
pain conditions with movement-associated fear-avoidance be-
havior as inappropriate exercise dosage may cause symptom
exacerbation [29]. Therefore, monitoring the magnitude of
MEP elicited by the chosen modality and dosage of exercise
may provide valuable information on the efficacy of a training
intervention aiming at reducing pain and improving shoulder
function in BCS with persistent pain as general recommenda-
tions may not be appropriate. Furthermore, this approach
could be useful to guide the rehabilitation early in the cancer
treatment continuum, where exercise may limit treatment-
related upper extremity impairments [30].
Shoulder strength and active range of motion
The results of this study demonstrate a significant reduction in
strength and active ROM of the affected shoulder in BCS ≥1.5
years beyond treatment as compared with healthy controls.
Our findings also provide preliminary evidence that strength
and ROM remain affected in some movement directions like
horizontal shoulder extension, but may have recovered to nor-
mal levels in others like internal shoulder rotation. The ob-
served reductions were greater than the previously reported
MDCs for active ROM (MDC: 8.4 −20.8°) in shoulder flexion
and horizontal shoulder extension, and for MIMS (MDC
0.09–0.19 Nm/kg FFM) in shoulder adduction [16], and are
considered clinically significant for these movement direc-
tions. These movement-specific impairments are different
from previous studies who report a general reduction in shoul-
der strength and ROM in BCS regardless of movement direc-
tion [31–36], which may be largely explained by differences
in methodological approaches and design between studies.
For example, only a few other case-control studies have eval-
uated shoulder function after breast cancer treatment in
comparison to healthy controls [35, 36]. In contrast, several
studies have employed a cross-sectional design for assessing
shoulder strength and ROM (both active and passive) in BCS
by comparing the affected and unaffected limbs [31, 32, 34].
However, this approach may underestimate the loss of shoul-
der function as shoulder morbidity after breast cancer can be
bilateral [15] and makes it difficult to distinguish longer-term
treatment-related reductions from age-related decline.
Another potential explanation for the observed differences
in shoulder impairment from previous investigations may be
variability in proximity to the treatment when obtaining the
measurements. For example, this study was performed on
average 66.1 months post-treatment compared with approxi-
mately 6 months [35], 18 months [10], 32 months [31], 44
months [32], 47 months [33] and 51 months [36] in previous
investigations. Greater shoulder impairment has been reported
closer to the treatment [7]. Hence, it could be speculated that
the movement-specific impairments observed in this study are
a product of variable long-term recovery for the tissues in-
volved. Muscles such as the pectorals are strongly affected
by surgery and/radiotherapy for breast cancer, which can
cause scar tissue formation and soft tissue fibrosis [37]. This
can impair normal gliding between skin-related structures,
fasciae, and muscles [9] and may never completely disappear
[37]. In contrast, muscles affected indirectly such as the rhom-
boid and trapezius muscles may have recovered to normal
levels at 66.1 months after breast cancer treatment, despite
significant impairments in closer proximity to treatment
[38]. However, all of the affected movement directions in this
study involved the pectorals, and thus, reduced pectoralis
minor- and major muscle flexibility and contractility from
permanent scar tissue formation could be a potential cause
for the movement-specific loss of an active ROM.
Strengths and limitations
The current study is the first to our knowledge to examine pain
and shoulder function concurrently in BCS with persistent
pain ≥1.5 years after treatment. In addition, we demonstrate
for the first time that this population exhibit MEP in the af-
fected shoulder and that intensity of MEP has a strong nega-
tive correlation with mechanical pain sensitivity. However,
this study is not without limitations. The measurements were
only performed unilaterally on the operated side for BCS and
future studies should also investigate if the widespread me-
chanical hyperalgesia and the decreases in shoulder function
are bilateral as indicated in previous studies [6, 15]. For ex-
ample, the inclusion of self-reported multidimensional pain
scales, such as the central sensitization index or the pain sen-
sitivity questionnaire could have complimented our findings
but none of these measures have been validated in Danish.
Further, pain can fluctuate over time, [39] and consequently,
the results of the present study are only representative of the
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pain experienced by each participant at the time of assessment.
Finally, multiple non-treatment risk factors for persistent pain
in BCS have been identified [40]; therefore, due to the cross
sectional study design, the results of this study cannot be used
to infer causality between treatment for breast cancer and pain.
Conclusion
The results of the present study showed that BCS with persis-
tent pain ≥1.5 years after treatment demonstrate clinically sig-
nificant reductions in pressure pain thresholds, strength, and
active ROM and exhibit greater MEP when compared with
asymptomatic controls. The widespread mechanical
hyperalgesia can be interpreted as sign of central sensitization
in BCS with persistent pain, and was negatively correlated
with the intensity of MEP during assessment of shoulder
strength. Hence, assessing MEP may be of relevance to clini-
cians when investigating physical function and performance
in BCS with persistent pain after treatment. Further, the
movement-specific deficits observed for shoulder strength
and active ROM in this population imply that the muscles
involved in these movement directions may benefit from be-
ing targeted directly through strengthening exercise, such as
resistance training.
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